Journal of Pharmacy And Bioallied Sciences

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 12  |  Issue : 3  |  Page : 269--276

Relationship between clinical trials and disease burden of India: A cross-sectional study


Rimplejeet Kaur1, Jaykaran Charan2, Tea Reljic3, Surjit Singh2, Pankaj Bhardwaj4, Athanasios Tsalatsanis3, Ambuj Kumar3 
1 Department of Pharmacology, S. N. Medical College, Jodhpur, Rajasthan, India
2 Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India
3 Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Research Methodology and Biostatistics Core, Office of Research, Tampa, Florida, USA
4 Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India

Correspondence Address:
Dr. Jaykaran Charan
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Jodhpur 342001, Rajasthan
India

Background: Research output/efforts in a country should be reflective of the disease burden. India is a site for several national and multinational clinical trials. However, whether clinical trials performed in India reflect the disease burden is not well known. Objectives: The aim of this study was to evaluate the relationship between disease burden and clinical trials performed in India. Materials and Methods: We extracted data on the disease burden from the World Health Organization (WHO) website and on characteristics of clinical trials performed in India from the Clinical Trial Registry of India (CRTI). The correlation between disease burden parameters of overall mortality, disability-adjusted life years (DALYs), years lost due to disability (YLD) and years of life lost (YLL), and the frequency of clinical trials associated with a particular disease was assessed. Additional subgroup analysis according to the number of trial centers, study phase, and medicine type was also performed. Results: Only 18% of clinical trials addressed top 10 diseases associated with 68.3% of overall mortality, and 8% of clinical trials addressed top 10 diseases associated with 52.3% of DALYs. Similarly, 16% of clinical trials addressed top 10 diseases associated with 53.2% YLDs. Furthermore, top 10 diseases associated with 65.9% of YLLs were addressed in only 8% of ongoing clinical trials. The overall correlation between any disease burden parameters with the diseases being explored in clinical trials was poor. Conclusion: There is a mismatch between diseases for which clinical trials are happening in the India and the disease burden of India. Measures need to be taken to fulfill this gap between demand and need.


How to cite this article:
Kaur R, Charan J, Reljic T, Singh S, Bhardwaj P, Tsalatsanis A, Kumar A. Relationship between clinical trials and disease burden of India: A cross-sectional study.J Pharm Bioall Sci 2020;12:269-276


How to cite this URL:
Kaur R, Charan J, Reljic T, Singh S, Bhardwaj P, Tsalatsanis A, Kumar A. Relationship between clinical trials and disease burden of India: A cross-sectional study. J Pharm Bioall Sci [serial online] 2020 [cited 2022 Jul 2 ];12:269-276
Available from: https://www.jpbsonline.org/article.asp?issn=0975-7406;year=2020;volume=12;issue=3;spage=269;epage=276;aulast=Kaur;type=0